Bioatla to participate in the h.c. wainwright 25th annual global investment conference

San diego, sept. 06, 2023 (globe newswire) -- bioatla, inc. (nasdaq: bcab), a global clinical-stage biotechnology company focused on the development of conditionally active biologic (cab) antibody therapeutics for the treatment of solid tumors, today announced that the company's management will provide a corporate update and participate virtually in scheduled one-on-one investor meetings at the h.c. wainwright 25th annual global investment conference, to be held september 11-13, 2023.
BCAB Ratings Summary
BCAB Quant Ranking